(0.64%) 5 079.00 points
(0.38%) 38 212 points
(0.87%) 17 590 points
(0.86%) $79.68
(2.38%) $1.978
(0.15%) $2 314.40
(-0.24%) $26.69
(1.03%) $964.70
(0.14%) $0.934
(0.29%) $11.06
(0.06%) $0.799
(-1.26%) $92.09
3 days till quarter result
(bmo 2024-05-05)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea...
Stats | |
---|---|
今日成交量 | 552 607 |
平均成交量 | 645 636 |
市值 | 40 884.38B |
EPS | KRW0 ( 2024-02-29 ) |
下一个收益日期 | ( KRW1 008.85 ) 2024-05-05 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 44.32 |
ATR14 | KRW197.42 (0.11%) |
音量 相关性
Celltrion, Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Celltrion, Inc. 相关性 - 货币/商品
Celltrion, Inc. 财务报表
Annual | 2023 |
营收: | KRW2 176.43B |
毛利润: | KRW2 176.43B (100.00 %) |
EPS: | KRW3 658.73 |
FY | 2023 |
营收: | KRW2 176.43B |
毛利润: | KRW2 176.43B (100.00 %) |
EPS: | KRW3 658.73 |
FY | 2022 |
营收: | KRW2 283.97B |
毛利润: | KRW1 032.70B (45.22 %) |
EPS: | KRW3 894.00 |
FY | 2021 |
营收: | KRW1 911.60B |
毛利润: | KRW1 101.42B (57.62 %) |
EPS: | KRW4 302.16 |
Financial Reports:
No articles found.
Celltrion, Inc.
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。